SARS-CoV-2 - Azithromycin - Therapeutic Candidates

SARS-CoV-2 - Azithromycin - Therapeutic Candidates


Azithromycin is a macrolide antibiotic. This broad-spectrum antibiotic of the azalide group is a derivative of erythromycin. Azithromycin is indicated for the treatment of certain types of mild to moderate infections caused by bacteria. Most commonly, it is used to treat ear infections such as otitis media, throat and lung infections such as pharyngitis and pneumonia, and certain skin infections. Azithromycin is also prescribed to patients with cystic fibrosis because they are particularly susceptible to respiratory infections.
A recent study, in the context of the Covid-19 epidemic currently affecting many countries around the world, sought to investigate the effect of azithromycin in combination with hydroxychloroquine. The interest in azithromycin came from the fact that the rate of Covid-19 infection was low in a large cohort of patients with cystic fibrosis, many of whom are on azithromycin therapy.

Search result : 277 product found

Refine your search :

RUOCE / IVD
  • Unconjugated 38
  • Biochemicals 231
  • Inhibitor/Antagonist/Agonist 42
  • Buffers and reagents 2
  • cell culture products 2
  • Assay 3
  • Cell culture 2
APPLY FILTERS
REINITIALIZE


Cat#
Description
Cond.
Price Bef. VAT
NB-42-00091-5g
 5g 
NB-48-0175-500MG
 500mg 
NB-42-00091-1g
 1g 
B1398-50mg
 50mg 
orb1300799-200mg
 200mg 
orb1300799-50mg
 50mg 
orb1223898-50mg
 50mg 
orb1223898-200mg
 200mg 
orb1223898-100mg
 100mg 
orb1300799-100mg
 100mg 
orb1223898-25mg
 25mg 
orb1300799-500mg
 500mg 
orb1308671-20mg
 20mg 
orb1900396-25mg
 25mg 
orb1900395-250mg
 250mg 
orb1900397
 10mm 
orb1900394-50mg
 50mg 
orb134667-1g
 1g 
orb1900398-100mg
 100mg